FindTrial
Sign In

BIIB017 (peginterferon beta-1a)

DRUG3 trials

Sponsors

Biogen

Conditions

Multiple Sclerosis, Relapsing-RemittingRelapsing Multiple Sclerosis

Phase 3

Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis
CompletedNCT00906399
BiogenRelapsing Multiple Sclerosis
Start: 2009-06-30End: 2013-10-31Updated: 2014-09-19
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
Active, not recruitingNCT03958877
BiogenMultiple Sclerosis, Relapsing-Remitting
Start: 2019-10-18End: 2027-05-20Updated: 2025-09-11

Phase 4

Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy
WithdrawnNCT02234869
BiogenRelapsing Multiple Sclerosis
Start: 2014-10-31End: 2018-03-31Updated: 2014-11-17

Related Papers

Privacy-by-Design Approach to Generate Two Virtual Clinical Trials for Multiple Sclerosis and Release Them as Open Datasets: Evaluation Study.
2025-10-01
Radiomics-based Unsupervised Clustering of Acute Multiple Sclerosis Lesions (P10-3.015)
Neurology2023-04-251 citations
Deep Learning Reconstruction of Lesion-Free Representations of the Brain in Multiple Sclerosis Patients (P11-3.006)
Neurology2023-04-25
Multiple sclerosis clinical decision support system based on projection to reference datasets
Annals of Clinical and Translational Neurology2022-11-227 citations
Abnormalities in normal-appearing white matter from which multiple sclerosis lesions arise
Brain Communications2021-01-0128 citations
Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring
Multiple Sclerosis Journal2020-12-1440 citations
Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis
Therapeutic Advances in Neurological Disorders2018-01-019 citations
Measuring the impact of multiple sclerosis: Enhancing the measurement performance of the Multiple Sclerosis Impact Scale (MSIS-29) using Rasch Measurement Theory (RMT)
Multiple Sclerosis Journal - Experimental Translational and Clinical2017-08-157 citations
Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial
BMC Neurology2017-02-0925 citations
Peginterferon beta-1a reduces disability worsening in relapsing–remitting multiple sclerosis: 2-year results from ADVANCE
Therapeutic Advances in Neurological Disorders2016-11-1615 citations
Number Needed to Treat Analysis Comparing Teriflunomide and Injectable Disease-Modifying Therapies (P6.173)
Neurology2016-04-051 citations
Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis
Multiple Sclerosis Journal - Experimental Translational and Clinical2016-01-0112 citations
Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis.
2015-06-1415 citations
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
2014-12-3135 citations
Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE
Multiple Sclerosis Journal2014-11-28112 citations
ADVANCE Results: PEG-IFN- -1a Decreases Disability in RRMS
MD Conference Express2014-06-01
Relapsing-Remitting Multiple Sclerosis Effectively Treated with Peginterferon Beta-1
MD Conference Express2014-06-01
Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
2014-04-30267 citations